{"id":"W2081446512","doi":"10.1038/bcj.2014.71","title":"Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Takeda Pharmaceuticals International; Takeda Oncology; Weill Cornell Medical College","keywords":"Medicine; Ixazomib; Follicular lymphoma; Nausea; Internal medicine; Neutropenia; Tolerability; Adverse effect; Pharmacodynamics; Gastroenterology; Lymphoma; Proteasome inhibitor; Pharmacokinetics; Pharmacology; Multiple myeloma; Toxicity; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002534996,0.0001801028,0.0003420601,0.000194792,0.00009195303,0.00002841527,0.00007290313,0.00006828802,0.0000615723],"category_scores_gemma":[0.00005101791,0.0001284452,0.0000464325,0.0002083538,0.00005055835,0.0003041739,0.0000158432,0.0001366439,0.000002317401],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002844149,"about_ca_system_score_gemma":0.0004819145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002102274,"about_ca_topic_score_gemma":0.0001400701,"domain_scores_codex":[0.9982742,0.0001443331,0.0004805592,0.0002385684,0.0006600888,0.0002022456],"domain_scores_gemma":[0.9988695,0.00003503045,0.0003675289,0.0002071538,0.0002613754,0.00025943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001260897,0.03615194,0.9324747,0.00002474841,0.0002008756,0.00002523763,0.000865834,0.00005856552,0.0002706682,0.00001724776,0.00007341853,0.02857586],"study_design_scores_gemma":[0.1032868,0.01447297,0.8798629,0.0003211006,0.0002941159,0.00002496739,0.0001198329,0.00007977062,0.001238545,0.00004830162,0.0001272279,0.0001234933],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998659,0.0001400335,0.000004007082,0.0001286127,0.000136781,0.0008264788,0.00001072511,0.00001340028,0.00008101323],"genre_scores_gemma":[0.999091,0.0000176765,0.0002590664,0.0001154579,0.0003231431,0.0001257472,0.00002685712,0.00002418159,0.00001683241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1020259,"threshold_uncertainty_score":0.5237845,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01404684565484182,"score_gpt":0.2736524728493425,"score_spread":0.2596056271945006,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}